Cullinan Therapeutics Inc (CGEM) - News Archive

Trailblazing in Autoimmune Therapies: Cullinan Therapeutics Garners FDA IND Clearance for CLN-978 in Lupus Treatment In a significant stride for autoimmune disease treatment, Cullinan Therapeutics Inc. recently received...

Cullinan Therapeutics Embarks on Groundbreaking Global Phase 1 Clinical Trial for Systemic Lupus ErythematosusIn a significant leap forward for autoimmune disease research, Cullinan Therapeutics, a division of Cullinan...

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus In a noteworthy move for both the company and pat...

for CSIMarket.com : The emergence of targeted therapies has revolutionized the treatment landscape for non-small cell lung cancer (NSCLC), especially for patients harboring specific mutations in the epidermal growth fac...

Pioneering Progress: Cullinan Therapeutics Announces Promising Results from the Phase 2b REZILIENT1 Study of Zipalertinib in NSCLC with EGFR Exon 20 Insertion Mutations In the ever-evolving landscape of oncology researc...

Cullinan Therapeutics, a biopharmaceutical company focused on modality-agnostic targeted therapies, is set to present clinical data from its Phase 1 trial of CLN-619 at the upcoming 2024 American Society of Clinical Onc...

Cullinan Therapeutics, an emerging leader in the development of advanced therapies to treat unmet medical needs, has announced its strategic expansion into the field of autoimmune diseases; a significant move marking a...

Cullinan Therapeutics Raises $280 Million in Private Placement FundingIn a recent announcement, Cullinan Therapeutics has successfully secured $280 million in a private placement funding round. The financing, which incl...

Cullinan Oncology, a biopharmaceutical company focused on developing novel cancer treatments, recently announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational Ne...

CAMBRIDGE, Mass., Dec. 14, 2023 - Cullinan Oncology, Inc. (Nasdaq: CGEM), a leading biopharmaceutical company specializing in modality-agnostic, targeted oncology therapies, announced today the initiation of a Phase 1 c...